[Costs associated with multiresistant bacteria in neurorehabilitation]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Oct;60(10):1075-1082. doi: 10.1007/s00103-017-2606-x.
[Article in German]

Abstract

Background and objectives: The number of patients with multiresistant bacteria (MRB) in rehabilitation facilities is increasing. The increasing costs of hygienic isolation measures reduce resources available for core rehabilitation services. In addition to the existing lack of care, patients with MRB are at further risk of being given lower priority for admission to rehabilitation facilities. Therefore, the Hygiene Commission of the German Society for Neurorehabilitation (DGNR) attempted to quantify the overall risk for deterioration of rehabilitation care due to the financial burden of MRB.

Materials and methods: To analyze the added costs associated with the rehabilitation of patients with MBR, the DGNR Hygiene Commission identified criteria for a cost assessment. Direct (consumables, personnel and miscellaneous costs) and indirect costs of loss of opportunity were evaluated in seven neurorehabilitation centers in different states across Germany.

Results: On average, hygienic isolation measures amounted to direct costs of 144 € per day (47 € consumables, 92 € personnel, 5 € for other costs such as extra transportation expenditure) and indirect costs of 274 €, totaling 418 € per patient with MRB per day. Given that approximately 10% of patients had MRB, the added costs of hygienic isolation measures equaled about one tenth of the overall budget of a rehabilitation center and can be expected to rise with the increasing numbers of patients with MRB.

Conclusions: Admission of patients carrying MRB to neurorehabilitation centers triggers added costs that critically diminish the overall capacity for centers to provide their core rehabilitation services.

Keywords: Antibiotic resistance; Health economy; Isolation measures; Neurorehabilitation; Rehabilitation.

Publication types

  • Review

MeSH terms

  • Bacterial Infections / drug therapy
  • Bacterial Infections / economics*
  • Bacterial Infections / prevention & control
  • Carrier State / economics
  • Cross Infection / drug therapy
  • Cross Infection / economics*
  • Cross Infection / prevention & control
  • Disinfection / economics
  • Drug Resistance, Multiple, Bacterial*
  • Germany
  • Health Care Costs / statistics & numerical data*
  • Health Expenditures / statistics & numerical data
  • Health Resources / economics
  • Methicillin-Resistant Staphylococcus aureus
  • National Health Programs / economics
  • Neurological Rehabilitation / economics*
  • Patient Admission / economics
  • Patient Isolation / economics
  • Quality of Health Care / economics
  • Risk Factors
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / economics
  • Staphylococcal Infections / prevention & control